The rationale for using somatostatin (octreotide0 is that it has been shown to inhibit the
secretion of various gastrointestinal hormones, including gastrin and secretin, which can
contribute to the development of non-variceal gastrointestinal bleeding (NVGIB). Somatostatin
has also been found to reduce splanchnic blood flow, which can decrease the risk of
rebleeding in patients with NVGIB.
Previous studies have suggested that somatostatin may be effective in reducing the risk of
rebleeding in patients with NVGIB, but there is a lack of high-quality randomized controlled
trials evaluating its efficacy.
Therefore, this study aims to provide more rigorous evidence regarding the use of
somatostatin in the management of NVGIB.
Aim of the study:
To evaluate the efficacy of medical treatment with somatostatin analogue (octreotide)
combined with PPI in the treatment of non-variceal gastrointestinal bleeding in comparison to
PPI alone a randomized.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
National Hepatology & Tropical Medicine Research Institute